Last updated: 2026-09-06 09:38:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cypherpunk Technologies Inc. (CYPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,42, with a market capitalization of $181,04M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,49 to $3,70. This page covers its latest market performance, valuation, price trends and company information.
$181,04M | |
$2,22 | |
$3,70 | |
$0,49 | |
$2,27 | |
14,97M | |
-- | |
-- | |
$3,70 | |
$0,49 | |
-- | |
-- |
Cypherpunk Technologies Inc. (CYPH) last closed at $2,27 as of 2026-09-05 00:00:00, unchanged from the previous close of $2,27.
During the latest regular trading session, CYPH traded between $0,49 and $3,70, with a volume of 14,97M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Cypherpunk Technologies Inc. (CYPH) moved from $1,74 to $2,42, representing a gain of 39,25% ($0,68).
The stock traded between $2,14 and $2,48 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 10,85 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 60,0%
CYPH is currently trading at $2,42, placing it 60,0% of the way from its 52-week low of $0,49 to its 52-week high of $3,70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cypherpunk Technologies Inc. (CYPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.